Request Demo
Recent blog posts
Latest Hotspot
8 min read
Enavogliflozin/Metformin hydrochloride Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Enavogliflozin/Metformin hydrochloride: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Dapagliflozin/Sitagliptin Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Dapagliflozin/Sitagliptin: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Niraparib Tosylate/Abiraterone Acetate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Niraparib Tosylate/Abiraterone Acetate: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Efgartigimod/Hyaluronidase Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Efgartigimod/Hyaluronidase: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Cholestatic pruritus Indication Strategy Report 2026: ISBT, Trials and Deals
21 July 2026
Cholestatic pruritus indication strategy report covering epidemiology, ISBT biology, active trials, competition and deal signals using PatSnap MCP evidence.
Latest Hotspot
8 min read
Microscopic colitis Indication Strategy Report 2026: IL-23p19, Trials and Deals
21 July 2026
Microscopic colitis indication strategy report covering epidemiology, IL-23p19 biology, active trials, competition and deal signals using PatSnap MCP evidence.
Latest Hotspot
8 min read
Irritable bowel syndrome Indication Strategy Report 2026: HTR3A, Trials and Deals
21 July 2026
Irritable bowel syndrome indication strategy report covering epidemiology, HTR3A biology, active trials, competition and deal signals using PatSnap MCP evidence.
Latest Hotspot
8 min read
Short bowel syndrome Indication Strategy Report 2026: GLP-2R, Trials and Deals
21 July 2026
Short bowel syndrome indication strategy report covering epidemiology, GLP-2R biology, active trials, competition and deal signals using PatSnap MCP evidence.
Latest Hotspot
8 min read
Adenomyosis Indication Strategy Report 2026: ERα, Trials and Deals
21 July 2026
Adenomyosis indication strategy report covering epidemiology, ERα biology, active trials, competition and deal signals using PatSnap MCP evidence.
Latest Hotspot
8 min read
Interstitial cystitis Indication Strategy Report 2026: TRPV1, Trials and Deals
21 July 2026
Interstitial cystitis indication strategy report covering epidemiology, TRPV1 biology, active trials, competition and deal signals using PatSnap MCP evidence.
Latest Hotspot
8 min read
Overactive bladder Indication Strategy Report 2026: β3-adrenergic receptor, Trials and Deals
21 July 2026
Overactive bladder indication strategy report covering epidemiology, β3-adrenergic receptor biology, active trials, competition and deal signals using PatSnap...
Latest Hotspot
8 min read
Benign prostatic hyperplasia Indication Strategy Report 2026: AR, Trials and Deals
21 July 2026
Benign prostatic hyperplasia indication strategy report covering epidemiology, AR biology, active trials, competition and deal signals using PatSnap MCP evidence.